The Wound Care Companies Every Rep Should Know
Wound care spans everyday dressings, negative-pressure therapy, and high-value skin substitutes. The major companies, from Smith+Nephew and Solventum to fast-growing biologics players.
*Publishing note for launch: every company name below (shown in bold) should link to its Vocari platform company page.*
Wound care rarely makes headlines, but it is everywhere, and it is big. Advanced wound care is a market of roughly $15 billion and growing, spanning products as simple as an advanced dressing and as complex as an engineered skin substitute.
That range makes it one of the more accessible and varied places to sell in medical devices. Here are the companies that lead it, and how the field breaks down.
What does wound care sales actually cover?
Three broad segments. Advanced dressings, foams, hydrofibers, and antimicrobials, are high-volume consumables used across every care setting. Negative-pressure wound therapy uses pumps and disposables to heal complex wounds. And skin substitutes and biologics, engineered or tissue-based grafts, are the high-value, high-growth, and most reimbursement-sensitive end.
Because the segments differ so much, so do the jobs. Dressings can be a friendlier, higher-volume entry point, while biologics selling is more technical and economics-driven.
Who are the biggest wound care companies?
A few leaders span the field:
- Smith+Nephew is a category leader across all three segments, with a roughly $1.8 billion advanced wound business spanning ALLEVYN dressings, bioactives, and PICO negative-pressure therapy.
- Solventum, spun out of 3M in 2024, leads negative-pressure therapy with the category-defining V.A.C. brand and a wound business near $1.9 billion.
- Molnlycke is a leader in foam dressings through its Mepilex and Mepitel lines.
- Convatec and Coloplast are major dressing players, with Coloplast expanding into biologics through its Kerecis fish-skin grafts.
Together they define the everyday and negative-pressure sides of the market.
Who leads the high-growth biologics side?
Skin substitutes and amniotic biologics are the fastest-growing, and most contested, part of wound care. Organogenesis grew about 17 percent to $563 million on grafts like Apligraf and PuraPly, and MiMedx grew about 20 percent to $419 million on amniotic tissue products like EpiFix. Integra LifeSciences and smaller players like Sanara MedTech round out the space.
The catch is reimbursement. Skin substitutes are highly sensitive to Medicare coverage policy, which has pressured parts of the category, so reps here live especially close to the payer landscape.
Is wound care a good place to build a career?
It is durable and varied. Demand is steady and aging-driven, the recurring-revenue dressing business is resilient, and the range of segments means there is a lane for almost every kind of rep, from high-volume dressing sales to technical biologics selling. Dressings in particular can be a friendlier entry into medical devices.
The main thing to watch is the reimbursement exposure on the biologics side. Beyond that, wound care offers a stable, growing, and often underrated place to build.
Key Takeaways
- Advanced wound care is a roughly $15 billion, growing market across dressings, negative-pressure therapy, and biologics.
- Smith+Nephew spans all three segments; Solventum leads negative-pressure therapy with the V.A.C. brand.
- Molnlycke, Convatec, and Coloplast are major dressing players; Coloplast is expanding into biologics.
- Organogenesis (about +17 percent) and MiMedx (about +20 percent) lead the fast-growing skin-substitute and biologics side.
- Dressings can be a newcomer-friendly entry; biologics selling is more technical and reimbursement-sensitive.
Frequently Asked Questions
What are the biggest wound care companies?
Smith+Nephew is a leader across dressings, biologics, and negative-pressure therapy, with a roughly $1.8 billion advanced wound business. Solventum, spun from 3M, leads negative-pressure therapy with its V.A.C. brand. Molnlycke, Convatec, and Coloplast are major dressing players, while Organogenesis and MiMedx lead the fast-growing biologics side.
What is wound care sales?
It is selling the products used to treat wounds, across three main segments: advanced dressings, negative-pressure wound therapy, and skin substitutes or biologics. The customers span hospitals, wound clinics, long-term care, and home health, and the segments range from high-volume consumables to high-value engineered grafts.
Is wound care sales a good career?
It can be a durable and varied one. Demand is steady and aging-driven, the recurring dressing business is resilient, and the range of segments offers a lane for many kinds of reps. Dressings can be a friendlier entry point, while biologics selling is more technical and sensitive to reimbursement policy.
Which wound care companies are growing fastest?
The skin-substitute and amniotic-biologics companies. Organogenesis grew about 17 percent to $563 million and MiMedx about 20 percent to $419 million. Growth there is strong but closely tied to Medicare reimbursement policy, which has pressured parts of the category.
Related Reading
- The Medical Device Companies Every New Rep Should Know
- How Reimbursement and Payers Shape Medical Sales
- How to Break Into Medical Device Sales With No Experience
About This Series
This guide is part of Vocari Intelligence, The Lobby’s series on how the medical sales business actually works, built from company financials and market data.
Exploring wound care? Set your parameters once on [Vocari](https://www.myvocari.com) and let matching roles come to you.